This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Five Oral Presentations On Clinical Experience With NanoKnife® System Featured At Society Of Interventional Radiology Conference

Stocks in this article: ANGO

AngioDynamics (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced oral presentations on NanoKnife ® System clinical experience took place at the Society of Interventional Radiology (SIR) 2012 Annual Scientific Meeting, March 24-29, 2012, in San Francisco, Calif.

An oral presentation titled “A prospective, multicenter phase II clinical trial using irreversible electroporation for the treatment of early stage HCC,” was given March 28, 2012. The authors of this Company-sponsored European study included Professors Riccardo Lencioni and Laura Crocetti of the University of Pisa, Pisa, Italy; Francesco Izzo of Istituto Nazionale Tumori – Fondazione Pascale, Naples, Italy; Valerie Vilgrain and Mohamed Abdel-Rehim of Hopital Beaujon, Paris, France; Jens Ricke and Maciej Pech of Universitatsklinikum Magdeburg AoR, Klinik fur Radiologie und Nuklearmedizin, Magdeburg, Germany; Jordi Bruix and Luis Bianchi of the Hospital Clinic i Provincial de Barcelona (BCLC), Barcelona, Spain.

The trial is a phase II prospective, multicenter clinical study to evaluate the efficacy and safety of the NanoKnife System as a first-line treatment for early-stage hepatocellular carcinoma (HCC), the most common form of liver cancer. It is registered with as number NCT01078415.

The following retrospective data analyses also were presented at SIR’s 2012 Annual Scientific Meeting.

An oral presentation titled “Downstaging locally advanced pancreatic adenocarcinoma (LAPC) with vascular encasement using percutaneous irreversible electroporation (IRE),” was given March 27 2012. The authors included Doctors Govindarajan Narayanan, Geetika Arora, Katuska Barbery, Tatiana Froud, Alan Livingstone, Dido Franceschi, Peter Hosein, Caio Rocha Lima, and Jose Yrizarry of the University of Miami, Miami, Fla.

Eight patients with biopsy-proven pancreatic cancer underwent percutaneous ablation of pancreatic tumors using the NanoKnife System. Imaging demonstrated intact veins in all patients’ treatment zones immediately, and 24-hours, after the procedure. Complications included spontaneous pneumothorax during anesthesia in one case and pancreatitis in one case. Both recovered completely. No mortalities occurred within 30 days. Follow up was conducted with each patient in the months after the procedure. This analysis also was the subject of a press release issued by SIR regarding the conference, as well as a press event hosted by the organization on March 26, 2012.

1 of 4

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs